Amicus Therapeutics prices IPO, raising up to $86M
Cranbury, N.J.-based Amicus Therapeutics priced its IPO shares at $15, right in the middle of its expected $14 to $16 range, an offering that could raise up to $86.3 million in gross proceeds if it sells all 5.75 million shares available. Here is the company’s release.
The company’s focus lies in developing “molecular chaperones” designed to help badly folded proteins achieve their true shape — thereby either restoring their function in genetic disease or potentially reducing… Continue Reading